EPO and cancer: In assessing an individual’s VTE risk, 2 points are assigned for very high-risk cancer types (e.g., stomach and pancreas), 1 point for high-risk cancer (e.g., lung, lymphoma, gynaecological, bladder, testicular), 1 point for baseline platelet count ≥ 350 × 109/L, 1 point for baseline leukocyte count > 11 × 109/L, 1 point for baseline haemoglobin level < 100 g/L or the use of erythropoietin, and 1 point for BMI ≥ 35 kg/m2 (Table 1) [17].